Quarterly ResultAug 5, 2026, 04:30 PM
Adicet Bio Q2 Net Loss Narrows to $21.4M; Cash for 12 Months
AI Summary
Adicet Bio reported a net loss of $21.4 million for Q2 2026, a significant improvement from $31.2 million in Q2 2025. For the first six months of 2026, the net loss was $41.6 million, down from $59.4 million in the prior year, driven by reduced operating expenses. The company expects its cash, cash equivalents, and short-term investments, totaling $118.2 million as of June 30, 2026, to fund operations for at least the next twelve months, supported by recent equity financings.
Key Highlights
- Q2 2026 net loss was $21.4 million, a decrease from $31.2 million in Q2 2025.
- Six-month 2026 net loss was $41.6 million, down from $59.4 million in the prior year.
- Research and development expenses decreased to $18.5 million in Q2 2026 from $28.4 million in Q2 2025.
- Cash, cash equivalents, and short-term investments totaled $118.2 million as of June 30, 2026.
- Accumulated deficit reached $656.3 million as of June 30, 2026.
- Net cash used in operating activities for six months 2026 was $41.3 million, down from $52.0 million in 2025.
- Raised approximately $91.7 million in January 2024 and $74.8 million in October 2025 through equity offerings.
Price Impact
More from ACET